BEAM Relative Valuation
BEAM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BEAM is overvalued; if below, it's undervalued.
Historical Valuation
Beam Therapeutics Inc (BEAM) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -10.83. The fair price of Beam Therapeutics Inc (BEAM) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：28.91
Fair
-6.20
PE
1Y
3Y
5Y
Trailing
Forward
-3.27
EV/EBITDA
Beam Therapeutics Inc. (BEAM) has a current EV/EBITDA of -3.27. The 5-year average EV/EBITDA is -8.90. The thresholds are as follows: Strongly Undervalued below -27.74, Undervalued between -27.74 and -18.32, Fairly Valued between 0.52 and -18.32, Overvalued between 0.52 and 9.94, and Strongly Overvalued above 9.94. The current Forward EV/EBITDA of -3.27 falls within the Historic Trend Line -Fairly Valued range.
-3.25
EV/EBIT
Beam Therapeutics Inc. (BEAM) has a current EV/EBIT of -3.25. The 5-year average EV/EBIT is -7.91. The thresholds are as follows: Strongly Undervalued below -24.52, Undervalued between -24.52 and -16.22, Fairly Valued between 0.40 and -16.22, Overvalued between 0.40 and 8.71, and Strongly Overvalued above 8.71. The current Forward EV/EBIT of -3.25 falls within the Historic Trend Line -Fairly Valued range.
43.37
PS
Beam Therapeutics Inc. (BEAM) has a current PS of 43.37. The 5-year average PS is 147.91. The thresholds are as follows: Strongly Undervalued below -457.30, Undervalued between -457.30 and -154.70, Fairly Valued between 450.51 and -154.70, Overvalued between 450.51 and 753.12, and Strongly Overvalued above 753.12. The current Forward PS of 43.37 falls within the Historic Trend Line -Fairly Valued range.
-8.37
P/OCF
Beam Therapeutics Inc. (BEAM) has a current P/OCF of -8.37. The 5-year average P/OCF is -16.46. The thresholds are as follows: Strongly Undervalued below -50.08, Undervalued between -50.08 and -33.27, Fairly Valued between 0.35 and -33.27, Overvalued between 0.35 and 17.16, and Strongly Overvalued above 17.16. The current Forward P/OCF of -8.37 falls within the Historic Trend Line -Fairly Valued range.
-7.68
P/FCF
Beam Therapeutics Inc. (BEAM) has a current P/FCF of -7.68. The 5-year average P/FCF is -11.58. The thresholds are as follows: Strongly Undervalued below -27.83, Undervalued between -27.83 and -19.70, Fairly Valued between -3.45 and -19.70, Overvalued between -3.45 and 4.67, and Strongly Overvalued above 4.67. The current Forward P/FCF of -7.68 falls within the Historic Trend Line -Fairly Valued range.
Beam Therapeutics Inc (BEAM) has a current Price-to-Book (P/B) ratio of 2.95. Compared to its 3-year average P/B ratio of 2.55 , the current P/B ratio is approximately 15.84% higher. Relative to its 5-year average P/B ratio of 5.22, the current P/B ratio is about -43.48% higher. Beam Therapeutics Inc (BEAM) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -12.32%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -7.50% , the current FCF yield is about -100.00% lower.
2.95
P/B
Median3y
2.55
Median5y
5.22
-13.35
FCF Yield
Median3y
-12.32
Median5y
-7.50
Competitors Valuation Multiple
The average P/S ratio for BEAM's competitors is 0.00, providing a benchmark for relative valuation. Beam Therapeutics Inc Corp (BEAM) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -32.03%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BEAM increased by 16.57% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -677.47 to -1.16K.
The secondary factor is the P/E Change, contributed -22.98%to the performance.
Overall, the performance of BEAM in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Beam Therapeutics Inc (BEAM) currently overvalued or undervalued?
What is Beam Therapeutics Inc (BEAM) fair value?
How does BEAM's valuation metrics compare to the industry average?
What is the current P/B ratio for Beam Therapeutics Inc (BEAM) as of Dec 05 2025?
What is the current FCF Yield for Beam Therapeutics Inc (BEAM) as of Dec 05 2025?
What is the current Forward P/E ratio for Beam Therapeutics Inc (BEAM) as of Dec 05 2025?